U.S-based biotech company IdentifySensors, developer of graphene-based biosensors, has announced plans to commercialize its disease testing technology and seek new funding in 2026.
On its website, the Company states that its Check4™ platform enables rapid, lab-free detection of cancers, viruses, and bacteria – no technicians or liquid reagents required. This sensitive, low-cost, electronic biosensor system aims to deliver multiplex molecular testing to the masses, with early cancer screening at its core.
As part of the Company’s process, graphene-based semiconductors are printed into solid-state circuits to become biosensors. The technology is intended to move diagnostics away from chemical testing and into a rapid multiplex digital platform with a lower limit of detection than the most accurate PCR tests on the market today.